Provepharm, a French company specialising in the development of pharmaceutical applications and Dr Franz Kohler Chemie (DFKC), manufacturer and supplier of organ preservation solutions and antidote pharmaceuticals, have entered into a partnership to launch Provepharm’s drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Under the agreement, DFKC is responsible for all commercial activities relating to the product in Germany.
The Provepharm Proveblue Methylene Blue active substance is said to be the first Methylene Blue grade to meet European Pharmacopeia standards.
“We are pleased to be collaborating with DFKC which has such a good understanding of the antidotes market in Germany and we appreciate Dr G. Kohler’s decision to make the medicinal product available to German users and patients,” says Michel Feraud, ceo and founder of Provepharm.
“We are delighted to be collaborating with Provepharm with whom we share similar values and goals. The launch of the medicinal product in Germany contributes to our company’s strategy to launch products responding to medical needs,” says Dr Gernot Kohler, ceo of DFKC.